Andreas Argyrides
Stock Analyst at Oppenheimer
(4.34)
# 1,251
Out of 4,442 analysts
391
Total ratings
46.5%
Success rate
9.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintained: Buy | $11 | $5.78 | +90.31% | 6 | Jun 3, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Buy | $40 | $20.26 | +97.43% | 9 | May 21, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $5.03 | +59.05% | 19 | May 15, 2026 | |
| UTHR United Therapeutics | Rated: Hold | n/a | $544.33 | - | 19 | May 11, 2026 | |
| LRMR Larimar Therapeutics | Rated: Hold | n/a | $3.68 | - | 8 | May 11, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $12.88 | - | 3 | May 11, 2026 | |
| LQDA Liquidia | Rated: Hold | n/a | $74.04 | - | 17 | May 11, 2026 | |
| GOSS Gossamer Bio | Rated: Hold | n/a | $0.1714 | - | 19 | May 11, 2026 | |
| MNPR Monopar Therapeutics | Rated: Hold | n/a | $81.77 | - | 4 | May 11, 2026 | |
| KROS Keros Therapeutics | Rated: Hold | n/a | $11.00 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $21.22 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.28 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.93 | - | 8 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $5 | $1.91 | +161.78% | 4 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $98 | $66.17 | +48.10% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $4.08 | +145.10% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $34.16 | +81.50% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $24.25 | +73.20% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.89 | +376.19% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $17.26 | +114.37% | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $3.12 | +23,938.46% | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.755 | - | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.02 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $13.72 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $75 | $0.11 | n/a | 18 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $105 | $21.97 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.074 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $11.72 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $9.95 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $23.51 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $56.50 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $15.07 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $238.59 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8033 | n/a | 6 | Aug 25, 2022 |
Savara
Jun 3, 2026
Maintained: Buy
Price Target: $11
Current: $5.78
Upside: +90.31%
Dyne Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $40
Current: $20.26
Upside: +97.43%
Aquestive Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: $8
Current: $5.03
Upside: +59.05%
United Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $544.33
Upside: -
Larimar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $3.68
Upside: -
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $12.88
Upside: -
Liquidia
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $74.04
Upside: -
Gossamer Bio
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $0.1714
Upside: -
Monopar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $81.77
Upside: -
Keros Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $11.00
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $21.22
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.28
Upside: -
Apr 27, 2026
Rated: Hold
Price Target: n/a
Current: $3.93
Upside: -
Apr 24, 2026
Maintained: Buy
Price Target: $7 → $5
Current: $1.91
Upside: +161.78%
Apr 24, 2026
Maintained: Buy
Price Target: $105 → $98
Current: $66.17
Upside: +48.10%
Mar 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $4.08
Upside: +145.10%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $34.16
Upside: +81.50%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $24.25
Upside: +73.20%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $1.89
Upside: +376.19%
Oct 9, 2025
Maintained: Buy
Price Target: $37
Current: $17.26
Upside: +114.37%
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $3.12
Upside: +23,938.46%
Jul 17, 2025
Rated: Hold
Price Target: n/a
Current: $0.755
Upside: -
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.02
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $13.72
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $5 → $75
Current: $0.11
Upside: n/a
Aug 13, 2024
Maintained: Hold
Price Target: $105
Current: $21.97
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.074
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $11.72
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $9.95
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $23.51
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $56.50
Upside: n/a
Feb 22, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $15.07
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $238.59
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $0.8033
Upside: n/a